IP Library › Granted Patent US 12,383,698
Granted Patent B2
US 12,383,698 · App. 18/979,950 · Granted Aug 12, 2025

Methods, systems, and apparatus for modulating or reducing photophobic responses

Inventors: Steven M. Blair (Salt Lake City, UT); Bradley Jay Katz (Salt Lake City, UT)
Assignee: University of Utah Research Foundation
A61M21/02A61N5/0618G02B5/22G02B5/285G02C7/104A61M2021/0044A61N2005/0663A61N2005/0667G02B5/289G02B2207/101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,698
App. No.
18/979,950
Granted
Aug 12, 2025
Kind
B2
Abstract

An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light in certain wavelengths, and to transmit more than a second amount of light weighted across the visual spectral response. Methods of use and methods of manufacturing optical filters are also described.

Claims (178)

1. An apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling exposure of cells in a retina, relative to a visible spectrum range of 400 nm to 700 nm, the apparatus comprising:

an optical filter configured to transmit:

light averaged across a first wavelength range of between 565 nm and 615 nm, wherein the transmitted light across the first wavelength range is a dose of light experienced by receptive cells of a subject (D rec,590 ),

light averaged across a second wavelength range of between 454 nm and 506 nm, wherein the transmitted light across the second wavelength range is a dose of light experienced by receptive cells of a subject (D melan ),

light averaged across a third wavelength range within a visible spectrum less than about 454 nm, between 506 nm and 565 nm, and greater than 615 nm, the transmitted light across the third wavelength range is a dose of light experienced over the visual spectrum (D vis ), and

wherein a ratio including the light across the first wavelength range and the light across the third wavelength range is defined as a figure of merit (FOM 1 ) of the optical filter, the figure of merit being determined by:

FOM

1

=

1

-

D

rec

,

590

D

rec

,

590

(

T

=

1

)

1

-

D

vis

D

vis

(

T

=

1

)

where D rec,590 (T=1) is the light across the first wavelength range in the absence of an optical filter, and D vis (T=1) is the light across the third wavelength range in the absence of an optical filter, wherein the figure of merit (FOM 1 ) is at least 1.3,

wherein a ratio including the light across the second wavelength range and the light across the third wavelength range is defined as a figure of merit (FOM 2 ) of the optical filter, the figure of merit being determined by:

FOM

2

=

1

-

D

melan

D

rmelan

(

T

=

1

)

1

-

D

vis

D

vis

(

T

=

1

)

where D melan (T=1) is the light across the second wavelength range in the absence of an optical filter, and D vis (T=1) is the light across the third wavelength range in the absence of an optical filter, wherein the figure of merit FOM 2 is at least 1.3;

wherein the optical filter includes a dye; and

wherein the optical filter has chromaticity coordinates where the x-coordinate is between 0.367 and 0.386 and the y-coordinate is between 0.359 and 0.376.

2. The apparatus of claim 1 , wherein the figure of merit FOM 2 is at least 2.0.

3. An apparatus for reducing the frequency and/or severity of photophobic responses by controlling light exposure to melanopsin ganglion cells in a retina, relative to a visible spectrum range of 400 nm to 700 nm, the apparatus comprising:

an optical filter configured with:

a light transmission fraction, averaged across wavelengths between 454 nm and 506 nm, less than an amount T melan , wherein T melan is a light across a first wavelength range in the absence of an optical filter; and

a light transmission fraction, averaged across wavelengths within a visible spectrum less than 454 nm and greater than 506 nm, greater than an amount T vis , wherein T vis is the light across a second wavelength range in the absence of an optical filter,

wherein a ratio including said light transmission fractions is defined as a figure of merit (FOM) of the optical filter, the figure of merit being determined by:

FOM

=

1

-

T

melan

1

-

T

vis

wherein the figure of merit of said optical filter is at least 1.3;

wherein the optical filter includes a dye; and

wherein the optical filter has chromaticity coordinates where the x-coordinate is between 0.367 and 0.386 and the y-coordinate is between 0.359 and 0.376.

4. An apparatus for reducing the frequency and/or severity of photophobic responses by controlling light exposure to melanopsin ganglion cells in a retina, relative to a visible spectrum range of 400 nm to 700 nm, the apparatus comprising:

an optical filter configured to transmit less than a first amount of light averaged across wavelengths between 454 nm and 506 nm, wherein said first amount of light is a dose of light experienced by the melanopsin ganglion cells of a subject (D melan ), and to transmit more than a second amount of light averaged across wavelengths within a visible spectrum less than 454 nm and greater than 506 nm, said second amount of light is a dose of light experienced over the visual spectrum (D vis ),

wherein a ratio including said first amount of light and said second amount of light is defined as a figure of merit (FOM), the figure of merit being determined by:

FOM

=

1

-

D

melan

D

melan

(

T

=

1

)

1

-

D

vis

D

vis

(

T

=

1

)

where D melan (T=1) is said first amount of light in the absence of an optical filter, and D vis (T=1) is said second amount of light in the absence of an optical filter, wherein the figure of merit of said optical filter is at least 1.3;

wherein the optical filter includes a dye; and

wherein the optical filter has chromaticity coordinates where the x-coordinate is between 0.367 and 0.386 and the y-coordinate is between 0.359 and 0.376.

5. An apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling exposure of cells in a retina, relative to a visible spectrum range of 400 nm to 700 nm, the apparatus comprising:

an optical filter configured to deliver:

a first dosage of light, averaged across wavelengths between 565 nm and 615 nm, said first dosage is D rec,590 ;

a second dosage of light, averaged across wavelengths between 454 nm and 506 nm, wherein said second dosage is D melan ; and

a third dosage of light, across wavelengths within a visible spectrum between 506 nm and 565 nm, wherein said third dosage is D grn ;

wherein a ratio including said second dosage of light and said third dosage of light is defined as a figure of merit (FOM 1 ), the figure of merit being determined by:

FOM

1

=

1

-

D

melan

D

melan

(

T

=

1

)

1

-

D

grn

D

grn

(

T

=

1

)

where D melan (T=1) is said second dosage of light in the absence of an optical filter, and D grn (T=1) is said third dosage of light in the absence of an optical filter, wherein the figure of merit is at least 1.3,

wherein a ratio including said first dosage of light and said third dosage of light is defined as a figure of merit (FOM 2 ), the figure of merit being determined by:

FOM

2

=

1

-

D

rec

,

590

D

rec

,

590

(

T

=

1

)

1

-

D

grn

D

grn

(

T

=

1

)

where D rec,590 (T=1) is said first dosage of light in the absence of an optical filter, and D grn (T=1) is said third dosage of light in the absence of an optical filter, wherein the figure of merit is at least 1.3, and

wherein the filter has chromaticity coordinates where the x-coordinate is between 0.367 and 0.386 and the y-coordinate is between 0.359 and 0.376.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2024
From: BLAIR, STEVEN M.; KATZ, BRADLEY JAY
To: UNIVERSITY OF UTAH
Reel/Frame 069592/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2024
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 069593/0511 →
Continuity (9)
Continuation 18304228 · Apr 20, 2023
Continuation 16800951 · Feb 25, 2020
Continuation 16445085 · Jun 18, 2019
Continuation 15673264 · Aug 9, 2017
Continuation In Part 14338182 · Jul 22, 2014
Continuation In Part 13979876 · Feb 24, 2014
Continuation In Part 14160374
Provisional Application 61433344 · Jan 17, 2011
Related Publication 20250108187A1 · Apr 3, 2025
References Cited (165)
US 4527183A · Anthony et al. · 1985 [cited by applicant]
US 5218386A · Levien · 1993 [cited by applicant]
US 5402190A · Waldman · 1995 [cited by applicant]
US 5737045A · Abileah · 1998 [cited by applicant]
US 5946114A · Loiseaux et al. · 1999 [cited by applicant]
US 6420032B1 · Iacovangelo · 2002 [cited by applicant]
US 6610081B2 · Saathoff · 2003 [cited by applicant]
US 7380940B2 · Anderson et al. · 2008 [cited by applicant]
US 7438411B2 · Payne et al. · 2008 [cited by applicant]
US 7556376B2 · Ishak et al. · 2009 [cited by applicant]
US 7854505B2 · Cunningham et al. · 2010 [cited by applicant]
US 7988318B1 · Smith et al. · 2011 [cited by applicant]
US 8345364B2 · Liberman et al. · 2013 [cited by applicant]
US 9606277B2 · Blair et al. · 2017 [cited by applicant]
US 9759848B2 · Blair et al. · 2017 [cited by applicant]
US 9764157B2 · Blair et al. · 2017 [cited by applicant]
US 10234608B2 · Blair et al. · 2019 [cited by applicant]
US 10281627B2 · Blair et al. · 2019 [cited by applicant]
US 10605970B2 · Blair et al. · 2020 [cited by applicant]
US 10914877B2 · Blair et al. · 2021 [cited by applicant]
US 20020044254A1 · Saathoff · 2002 [cited by applicant]
US 20020187347A1 · Halas et al. · 2002 [cited by applicant]
US 20030161257A1 · Yusu et al. · 2003 [cited by applicant]
US 20040085660A1 · Hara · 2004 [cited by applicant]
US 20050074611A1 · Kuehnle et al. · 2005 [cited by applicant]
US 20050149993A1 · Panda et al. · 2005 [cited by applicant]
US 20050164169A1 · Malak · 2005 [cited by applicant]
US 20060092374A1 · Ishak · 2006 [cited by applicant]
US 20060158732A1 · Ramadan · 2006 [cited by applicant]
US 20060189113A1 · Vanheusden et al. · 2006 [cited by applicant]
US 20070012189A1 · Kang et al. · 2007 [cited by applicant]
US 20070282437A1 · Hermitte et al. · 2007 [cited by applicant]
US 20070298242A1 · Huo · 2007 [cited by applicant]
US 20080065177A1 · Casper et al. · 2008 [cited by applicant]
US 20080221674A1 · Blum et al. · 2008 [cited by applicant]
US 20090022995A1 · Graham et al. · 2009 [cited by applicant]
US 20100149483A1 · Chiavetta, III · 2010 [cited by applicant]
US 20100246009A1 · Polley et al. · 2010 [cited by applicant]
US 20100328763A1 · Seo et al. · 2010 [cited by applicant]
US 20110009542A1 · Gong et al. · 2011 [cited by applicant]
US 20110060062A1 · Wang et al. · 2011 [cited by applicant]
US 20110075263A1 · Liberman et al. · 2011 [cited by applicant]
US 20110223255A1 · Thiesen et al. · 2011 [cited by applicant]
US 20120043512A1 · Liu et al. · 2012 [cited by applicant]
US 20130062637A1 · Reed et al. · 2013 [cited by applicant]
US 20130100443A1 · Li et al. · 2013 [cited by applicant]
US 20130130018A1 · Poncelet et al. · 2013 [cited by applicant]
US 20130258456A1 · Hashimura et al. · 2013 [cited by applicant]
US 20140135570A1 · Blair et al. · 2014 [cited by applicant]
US 20140160569A1 · Blair et al. · 2014 [cited by applicant]
US 20140303504A1 · Stankovic et al. · 2014 [cited by applicant]
US 20140320806A1 · Cohen-Tannoudji et al. · 2014 [cited by applicant]
US 20140327967A1 · Blair et al. · 2014 [cited by applicant]
US 20140329336A1 · Moriya et al. · 2014 [cited by applicant]
US 20150138661A1 · Blair et al. · 2015 [cited by applicant]
US 20150168616A1 · Blair et al. · 2015 [cited by applicant]
US 20150192800A1 · Dirk · 2015 [cited by examiner]
US 20150234207A1 · Koifman · 2015 [cited by applicant]
US 20160282532A1 · Le et al. · 2016 [cited by applicant]
US 20170336545A1 · Blair et al. · 2017 [cited by applicant]
US 20190154894A1 · Blair · 2019 [cited by applicant]
US 20190310405A1 · Blair et al. · 2019 [cited by applicant]
US 20200192011A1 · Blair et al. · 2020 [cited by applicant]
US 20210103080A1 · Blair et al. · 2021 [cited by applicant]
US 20230248937A1 · Blair et al. · 2023 [cited by applicant]
CN 103969725A · 2014 [cited by applicant]
CN 104115054A · 2014 [cited by applicant]
CN 111148482A · 2020 [cited by applicant]
DE 102005044031A1 · 2007 [cited by applicant]
DE 102007007777A1 · 2008 [cited by applicant]
DE 102011050870A1 · 2012 [cited by applicant]
EP 1566833A2 · 2005 [cited by applicant]
EP 1743691A1 · 2007 [cited by applicant]
EP 1991365B1 · 2014 [cited by applicant]
EP 2896423A1 · 2015 [cited by applicant]
JP 2004508106A · 2004 [cited by applicant]
JP 2005254446A · 2005 [cited by applicant]
JP 2006523593A · 2006 [cited by applicant]
JP 2007021473A · 2007 [cited by applicant]
JP 2007199421A · 2007 [cited by applicant]
JP 2008203377A · 2008 [cited by applicant]
JP 2009526132A · 2009 [cited by applicant]
JP 2009536549A · 2009 [cited by applicant]
JP 2010271022A · 2010 [cited by applicant]
JP 2011506747A · 2011 [cited by applicant]
JP 2011511330A · 2011 [cited by applicant]
JP 2012041534A · 2012 [cited by applicant]
JP 2012063715A · 2012 [cited by applicant]
JP 2013127489A · 2013 [cited by applicant]
JP 2014531058A · 2014 [cited by applicant]
JP 2015509742A · 2015 [cited by applicant]
JP 2017533449A · 2017 [cited by applicant]
JP 2018172778A · 2018 [cited by applicant]
JP 2020530587A · 2020 [cited by applicant]
JP 2020190749A · 2020 [cited by applicant]
KR 100611682B1 · 2006 [cited by applicant]
WO 0220079A1 · 2002 [cited by applicant]
WO 2004021071A1 · 2004 [cited by applicant]
WO 2004077453A2 · 2004 [cited by applicant]
WO 2006097794A1 · 2006 [cited by applicant]
WO 2007011331A2 · 2007 [cited by applicant]
WO 2007133197A1 · 2007 [cited by applicant]
WO 2009100195A1 · 2009 [cited by applicant]
WO 2010111499A1 · 2010 [cited by applicant]
WO 2012154535A1 · 2012 [cited by applicant]
WO 2012177296A1 · 2012 [cited by applicant]
WO 2013039117A1 · 2013 [cited by applicant]
WO 2013084176A1 · 2013 [cited by applicant]
WO 2014011581A2 · 2014 [cited by applicant]
WO 2015073933A1 · 2015 [cited by applicant]
WO 2016014713A1 · 2016 [cited by applicant]
WO 2016148984A1 · 2016 [cited by applicant]
WO 2019032348A1 · 2019 [cited by applicant]
Balzers et al., “Design of Optical Minus Filters,” Journal of the Optical Society of America, vol. 61, No. 3, (1971). [cited by applicant]
Berson et al., “Phototransduction by Retinal Ganglion Cells That Set the Circadian Clock,” Science, 295 (2002). [cited by applicant]
Blackburn “FL-41 Tint Improves Blink Frequency, Light Sensitivity, and Functional Limitations in Patients with Benign Essential Blepharospasm,” Ophthalmology 2009 116(5) 997-1001. [cited by applicant]
Czeisler “Sleep and Circadian Rhythms in Humans,” Cold Spring Harbor Symposia on Quantitative Biology, 2007, 72:579-97. [cited by applicant]
Czeisler, “The Effect of Light on the Human Circadian Pacemaker,” CIBA Foundation Symposium. 1995: 183:254-90. [cited by applicant]
Duffy JF, Wright KP Jr. Entrainment of the human circadian system by light. J Biol Rhythms. 2005;20(4):326-338. doi:10.1177/0748730405277983. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,478, mailed on Dec. 15, 2017. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,478, mailed on Jun. 2, 2017. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,564, mailed on Aug. 25, 2017. [cited by applicant]
Final Office Action received for U.S. Appl. No. 14/542,564, mailed on Jul. 30, 2018. [cited by applicant]
Final Office Action received for U.S. Appl. No. 15/673,264, mailed on Jan. 10, 2019. [cited by applicant]
Final Office Action received for U.S. Appl. No. 18/304,228, mailed on Sep. 3, 2024, 8 pages. [cited by applicant]
Good, P., Taylor, R. and Mortimer, M. (1991), The Use of Tinted Glasses in Childhood Migraine. Headache: The Journal of Head and Face Pain, 31: 533-536. doi:10.1111/j.1526-4610.1991.hed3108533.x. [cited by applicant]
Hannibal et al. “Roles of PACAP—Containing Retinal Ganglion Cells in Circadian Timing,” International Review of Cytology, 2006, vol. 251, pp. 1-39. [cited by applicant]
Hoggan et al., “Thin Film Optical Notch Filter Spectacle Coatings for the Treatment of Migraine and Photophobia,” In Press, Journal of Clinical Neuroscience, 2016. [cited by applicant]
International Search Report and Written Opinion for PCT/US2015/041610 dated Oct. 2, 2015. [cited by applicant]
International Search Report for PCT/US2014/065848 dated Mar. 5, 2015. [cited by applicant]
Kojima et al., “UV-Sensitive Photoreceptor Protein OPN5 in Humans and Mice,” PLoS One 6(10): e26388. doi:10.1371/journal.pone.0026388. [cited by applicant]
Larouche et al., “OpenFilters: Open-Source of Software for Optimization, and Synthesis of Optical Filters,” Applied Optics, vol. 47, No. 13, (2008). [cited by applicant]
Mure LS, Cornut PL, Rieux C, et al. Melanopsin bistability: a fly's eye technology in the human retina. PLoS One. 2009;4(6):e5991. Published Jun. 24, 2009. doi:10.1371/journal.pone.0005991. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/251,510, mailed on Jun. 16, 2020, 8 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/800,951, mailed on Mar. 28, 2022, 7 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 17/122,773, mailed on Aug. 30, 2024, 14 pages. [cited by applicant]
Noseda, Rodrigo et al. “A neural mechanism for exacerbation of headache by light.” Nature neuroscience vol. 13, 2 (2010): 239-45. doi:10.1038/nn.2475. [cited by applicant]
Office Action received for U.S. Appl. No. 13/979,876, mailed on Feb. 25, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/160,374, mailed on Apr. 7, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/160,374, mailed on Oct. 20, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/338,182, mailed on Nov. 29, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,478, mailed on Aug. 25, 2017. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,478, mailed on Jun. 22, 2018. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,478, mailed on Nov. 3, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,564, mailed on Jan. 10, 2018. [cited by applicant]
Office Action received for U.S. Appl. No. 14/542,564, mailed on Jun. 5, 2017. [cited by applicant]
Office Action received for U.S. Appl. No. 15/673,264, mailed on Sep. 20, 2018. [cited by applicant]
Office Action received for U.S. Appl. No. 16/445,085, mailed on Sep. 27, 2019. [cited by applicant]
Restriction Requirement received for U.S. Appl. No. 14/542,564, mailed on Nov. 2, 2016. [cited by applicant]
Satchidananda Panda et al., “Illumination of the Melanopsin Signaling Pathway,” Science, 307 (2005). [cited by applicant]
U.S. Appl. No. 13/979,876, filed Feb. 25, 2016, Office Action. [cited by applicant]
U.S. Appl. No. 14/160,374, filed Apr. 7, 2016, Office Action. [cited by applicant]
U.S. Appl. No. 14/160,374, filed Oct. 20, 2016, Office Action. [cited by applicant]
U.S. Appl. No. 14/338,182, Nov. 29, 2016, Office Action. [cited by applicant]
U.S. Appl. No. 14/542,564 dated Jun. 5, 2017, Office Action. [cited by applicant]
U.S. Appl. No. 15/673,264, filed Sep. 20, 2018, Office Action. [cited by applicant]
U.S. Appl. No. 14/542,564, filed Jul. 30, 2018, Final Office Action. [cited by applicant]
Wang et al., “Theory and Applications of Guided-Mode Resonance Filters,” Applied Optics, vol. 32, No. 14, (1993). [cited by applicant]
Bogoslovov et al. Effect of Silica Nanoparticles on the Local Segmental Dynamics in Poly(vinyl acetate), Macromolecules, 2008, vol. 41, pp. 1289-1296. [cited by applicant]
European Search Report received for EP Patent Application No. 23189866.9, mailed on Nov. 7, 2023, 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2012/021500 dated May 8, 2012. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/044835, mailed on Oct. 12, 2018, 9 pages. [cited by applicant]
Khlebtsov et al. “The Effect of the Size, Shape, and Structure of Metal Nanoparticles on the Dependence of Their Optical Properties on the Refractive Index of a Disperse Medium,” Optics and Spectroscopy, vol. 98,No. 1, … [cited by applicant]
Sahoo et al. “Residual Polyvinyl Alcohol Associated with Poly (D,L-lactide-co-glycolilde) Nanoparticles Affects Their Physical Properties and Cellular Uptake,” Journal of Controlled Release, vol. 82, 2002, pp. 105-114. [cited by applicant]
Willets et al. “Localized Surface Plasmon Resonance Spectroscopy and Sensing,” Annual Review in Physical Chemistry, vol. 58, 2007, pp. 267-297. [cited by applicant]